Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC

NCT07742332 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

160

Enrollment

OTHER

Sponsor class

Conditions

EGFR
NSCLC (Non-small Cell Lung Cancer)
Locally Advanced Non-Small Cell Lung Cancer
Radiotherapy
Chemotherapy

Interventions

DRUG: Fumetinib combined platinum-based double chemotherapy
COMBINATION_PRODUCT: Concurrent Radiochemotherapy

Sponsor

Peng Zhang